6-K ·Filed Apr 13, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001654954-26-003420
Notable filing: 6-K
Actionable Insight • Neutral

The share repurchase is a routine execution of GSK's announced buyback program and does not signal any change in strategy. Traders should monitor for larger cumulative buyback volumes over time rather than reacting to individual daily transactions.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
GSK ▼ -10.89% at T+60d
NEUTRAL call ✗ call lost -10.89% · α vs SPY -19.82% · entry $58.94 → $52.52
Entry anchored
Apr 10, 03:59 PM ET
via exchange tick
T+1d
+0.41%
call +0.41% · α -0.80%
$59.18
settled 6mo ago
T+5d
-2.70%
call -2.70% · α -5.99%
$57.35
settled 6mo ago
T+20d
-15.49%
call -15.49% · α -23.22%
$49.81
settled 5mo ago
T+60d
-10.89%
call -10.89% · α -19.82%
$52.52
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weighted average price of 2,182.28 GBp. This transaction increases the company's treasury shares to 258.1 million, representing 6.36% of voting rights.

Key Facts

  • GSK repurchased 325,000 ordinary shares on April 10, 2026
  • Purchase price ranged from 2,157.00p to 2,196.00p per share, with a volume-weighted average of 2,182.28p
  • Shares were purchased through BNP Paribas SA on multiple exchanges
  • Total treasury shares now stand at 258,112,615, or 6.36% of voting rights
  • The repurchase is part of an existing buyback program announced on February 17, 2026

Financial Impact

The repurchase represents a nominal investment of approximately £709 million (325,000 shares × 2,182.28 GBp), though the exact amount is not disclosed in the filing.

shares outstandingtreasury stockvoting rights

Risk Factors

  • The buyback could accelerate if the company has excess cash, potentially reducing capital available for R&D or acquisitions
  • Continued repurchases may limit downside protection if the stock price declines

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003420
Document: 0001654954-26-003420-index-headers.html0001654954-26-003420
Document: 0001654954-26-003420-index.html0001654954-26-003420
Document: 0001654954-26-003420.txt0001654954-26-003420
42 reports for GSK
Performance horizon
69% Hit rate 11 of 16 directional calls best @ T+60▲ +7.85%Jun 16, 2026
Filters
Rows
Reports for GSK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
6-K
NEUTRAL ★ 5/10
$50.01 $50.22▲ +0.42%▼ −0.40%$47.03 (−5.96%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 14, 2026
18d ago
6-K
BULLISH ★ 7/10
$50.05 $51.08▲ +2.06%▲ +1.95%$47.03 (−6.03%)
Sep 11, 2026
21d ago
6-K
NEUTRAL ★ 1/10
$48.13 $50.22▲ +4.34%▲ +4.56%$47.03 (−2.29%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 1/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 3/10
$48.12 $51.06▲ +6.11%▲ +6.61%$47.03 (−2.27%)
Sep 1, 2026
4w ago
6-K
NEUTRAL ★ 1/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 6/10
$50.66 $48.63▼ −4.01%▼ −4.09%$47.03 (−7.17%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 1/10
$51.43 $50.44▼ −1.92%▼ −1.80%$47.03 (−8.56%)
Aug 24, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$51.78 $50.25▼ −2.95%▼ −3.42%$47.03 (−9.17%)
Showing 10 of 42

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access